On Wednesday, in the course of current trade, Shares of AbbVie Inc. (NYSE:ABBV), gained 0.75%, and is now trading at $67.12.
Halozyme Therapeutics, Inc. declared a global partnership and license agreement with AbbVie (ABBV) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme’s ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling about $130 million for each of up to nine partnership targets. These payments are subject to AbbVie’s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay Halozyme tiered royalties if products under the partnership are commercialized.
The Halozyme ENHANZE platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs. For AbbVie, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis.
During an Afternoon trade, Shares of SunEdison, Inc. (NYSE:SUNE), gained 0.66%, and is now trading at $30.67.
NEXTracker, Inc., designer and manufacturer of the world’s most advanced single axis photovoltaic trackers, declared the completion of tracker commissioning for the SunEdison 82 megawatt Pacifico and Choluteca solar power plants in Honduras. SunEdison, Inc. (SUNE), the world’s largest renewable energy development company, developed and built the system.
Global demand for solar trackers continues to expand rapidly as the market has transitioned to higher irradiance locations where trackers deliver outstanding enhances in power production. NEXTracker’s technology is proven to be a cost-effective solution to maximize solar project returns. Advanced features address and overcome layout constraints, significantly reduce the number of foundations and use of steel, eliminate stress on the drive components by aligning modules with the axis of rotation, and simplify AC wiring requirements.
SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. The company operates through three segments: Solar Energy, TerraForm Power, and Semiconductor Materials.
Shares of PVH Corp. (NYSE:PVH), during its Wednesday’s current trading session gained 2.34%, and is now trading at $114.71.
PVH Corp., declared that Company administration will take part in the Thirty-Fifth Annual Piper Jaffray Consumer Conference on Wednesday, June 10, 2015. A live audio webcast of administration’s fireside chat will be broadcast online at 9:40 A.M. Eastern Daylight Time.
PVH Corp. operates as an apparel company in the United States and internationally. It designs, markets, and retails men’s and women’s apparel and accessories, branded dress shirts, neckwear, sportswear, jeanswear, intimate apparel, swim products, handbags, footwear, golf apparel, fragrances, cosmetics, eyewear, hosiery, socks, jewelry, watches, outerwear, small leather goods, and home furnishings, in addition to other related products.
Finally, Accuray Incorporated (NASDAQ:ARAY), gained 0.32% Wednesday.
Accuray Incorporated, declared that its administration team is planned to present at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 10, 2015 at 4:00pm PT.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
